NKTX 8-K: SEC filing
Nkarta
Filed with the SEC on · accession 0001787400-26-000027
NKTX filed a 8-K (current report) with the SEC on Nov 9, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Summary of the filing
Nkarta announced positive initial clinical data for NKX019 in myositis and systemic sclerosis from its Ntrust trials, showing high response rates and a favorable safety profile, and plans to discuss registrational paths with the FDA.
Key details
✦ Ask GOAX AI about this filing — what it means for NKTX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for NKTX?
Click hereFrequently asked questions
What did NKTX file with the SEC on Nov 9, 2026?
NKTX filed a 8-K (SEC filing). Nkarta announced positive initial clinical data for NKX019 in myositis and systemic sclerosis from its Ntrust trials, showing high response rates and a favorable safety profile, and plans to discuss registrational paths with the FDA.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other NKTX SEC filings
Get alerts when NKTX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days